利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.009 秒)

    POXVIRUS-BASED EXPRESSION VECTORS CONTAINING HETEROLOGOUS INSERTS DERIVED FROM LENTIVIRUSES
    4.
    发明公开
    POXVIRUS-BASED EXPRESSION VECTORS CONTAINING HETEROLOGOUS INSERTS DERIVED FROM LENTIVIRUSES 失效
    在其上的异源DNA插入来自慢病毒天花病毒-BASED表达载体含有

    公开(公告)号：EP0956360A4

    公开(公告)日：2003-04-23

    申请号：EP97946609

    申请日：1997-11-07

    申请人： VIROGENETICS CORP

    发明人： TARTAGLIA JAMES ,  PAOLETTI ENZO

    IPC分类号： C12N15/09 ,  A61K35/76 ,  A61K39/00 ,  A61K39/21 ,  A61K48/00 ,  B82B1/00 ,  C07K14/155 ,  C07K16/10 ,  C12P21/06 ,  A01N63/00 ,  A61K39/12 ,  A61K39/275 ,  C12N7/00 ,  C12N7/04 ,  C12N15/00

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K2039/525 ,  C12N2710/24043 ,  C12N2740/15022

    摘要： Recombinants containing and expressing lentivirus, retrovirus or immunodeficiency virus DNA and methods for making and using the same are disclosed and claimed. In an exemplified embodiment, attenuated recombinant viruses containing DNA encoding a feline immunodeficiency virus epitope such as an antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinants can be NYVAC or ALVAC recombinants. The DNA can encode at least one of: Env, Gag, Pol, or combinations thereof such as Gag and Pol or protease or Env, Gag and Pol or protease. The recombinants and gene products therefrom and antibodies generated by them have several preventive, therapeutic and diagnostic uses. DNA from the recombinants are useful as probes or, for generating PCR primers or for immunization. The immunogenicity and protective efficacy of immunization protocols involving ALVAC-FIV and priming with a recombinant canarypox virus ALVAC-FIV followed by a booster immunization with inactivated FIV-infected celled vaccine (ICV) was evaluated against FIV challenge in cats and the protocol was shown to effectively induce FIV-specific protective immune responses. Further, it was found that immunized cats were fully protected from an initial challenge with a slightly heterologous FIV strain (50CID50) and were partially protected from a second challenge with a distinctly heterologous FIV strain (75CID50) given eight months after the initial challenge without any intervening booster.